Pete Roden

CL Asset Holdings Ltd. provides property development, rental accommodation, and investment services. Its principal activities include property development, rental accommodation management, product trading and export, property funds management, and an investment in a marketing services and specialist broadcast equipment hire company. The company was founded on April 22, 2003 and is headquartered in Banksmeadow, Australia.

Western Oncolytics Ltd. develops novel therapies for cancer. The private company is based in Westlake. Helena H. Chaye has been the CEO of the American company since 2019.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Part of Gray Television, Inc., Fox & Carskadon is a real estate brokerage concern. The company is based in San Carlos, CA.

Booz Allen Hamilton, Inc. engages in the provision of management and technology consulting services. Its services include consulting, analytics, digital solutions, engineering, cyber security, and product. The company was founded by Edwin G. Booz in 1914 and is headquartered in McLean, VA.

FMR LLC engages in the provision of financial and investment services. It offers financial planning and advice, wealth management, retirement plans, trading and brokerage services, and investment products. The company was founded by Edward C. Johnson II in 1946 and is headquartered in Boston, MA.

Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye.